CHARLOTTESVILLE, VA, April 27 /CNW/ - Biovista announced today that it
has entered into a research collaboration agreement with Novartis. The
collaboration is focused on identifying new indications for a number of
undisclosed Novartis compounds using Biovista's Clinical Outcome Search
Space (COSS) technology.
The terms of the agreement include an upfront payment and success-based
"We look forward to working with Novartis to enhance their drug
discovery efforts" said Aris Persidis, President of Biovista. "Our
unique COSSTM technology offers significant advantages in terms of speed,
comprehensiveness and depth of clinical outcome exploration, which we
expect will help patients in need of novel solutions," he added.
Biovista is a privately held biotechnology company that finds novel uses
for existing drugs, and profiles their side effects using their
mechanism of action. Biovista is developing its own drug pipeline in
multiple indications and is collaborating with the FDA on the
prediction of adverse events, as well as with biopharmaceutical
companies on indication expansion and de-risking of their portfolios (http://www.biovista.com).
SOURCE Biovista Inc.
For further information: